Hodgkin lymphoma: is there really a need for interim and end-of-treatment FDG-PET evaluations?

Hugo J. A. Adams; Thomas C. Kwee

doi:10.1111/bjh.14495

Hodgkin lymphoma: is there really a need for interim and end-of-treatment FDG-PET evaluations?

Hugo J. A. Adams
, Thomas C. Kwee

Research output: Contribution to journal › Comment/Letter to the editor › Academic

14 Downloads (Pure)

Original language	English
Pages (from-to)	122-123
Journal	British journal of haematology
Volume	181
Issue number	1
DOIs	https://doi.org/10.1111/bjh.14495
Publication status	Published - 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1111/bjh.14495

Hodgkin-lymphoma-is-there-really-a-need-for-interim-and-end-of-treatment-fdg-pet-evaluations.pdfFinal published version, 58.5 KBLicence: Taverne

Cite this

@article{534860ce41f94c65aec2556a1d67dc54,

title = "Hodgkin lymphoma: is there really a need for interim and end-of-treatment FDG-PET evaluations?",

author = "Adams, \{Hugo J. A.\} and Kwee, \{Thomas C.\}",

year = "2018",

doi = "10.1111/bjh.14495",

language = "English",

volume = "181",

pages = "122--123",

journal = "British journal of haematology",

issn = "0007-1048",